桥接放疗在接受 CAR-T 治疗的复发/难治性弥漫大 B 细胞淋巴瘤中的作用：一项多中心研究

The optimization of bridging regimen before chimeric antigen receptor (CAR)-T cell therapy in diffuse large B-cell lymphoma (DLBCL) may impact CAR-T efficacy and outcome. This retrospective study evaluates CAR-T outcome after bridging with radiotherapy (RT) and other bridging strategies. Among 148 patients with relapsed/refractory DLBCL who underwent leukapheresis for CAR-T manufacturing, 31 received RT-bridging, 84 chemotherapy (CT), 33 no-bridging or steroid-only. CAR-T cell were infused in 96.

8% of RT-group, 89. 2% of CT-group and 78. 8% of no-bridge-group (p = 0. 079). Response to bridging was generally poor, but patients receiving RT had a significant reduction in LDH levels between pre- and post-bridging (p = 0. 05). The one-year PFS was 51. 2% in the RT-group, 28. 2% in the CT-group, and 47. 6% in the no-bridge-group (p = 0. 044, CT-bridging vs RT-bridging); 1-year OS was 86. 7% in the RT-group, 52. 7% in the CT-group and 69% in the no-bridge-group (p = 0. 025, CT-bridging vs RT-bridging).

We observed a higher incidence of ICANS in patients who received CT than in others (20. 0% CT-group, 3. 3% RT-group, 7. 7% no-bridge group; p = 0. 05).

In conclusion, RT-bridging is associated with lower drop-out rate and CAR-T toxicity, and it might be preferred to other bridging strategies for patients with localized disease or for those with one prevalent symptomatic site.